The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Hepatitis C Virus Infection and Cardiovascular Disease Risk

Patients with HCV infection have a higher risk for carotid atherosclerosis and cerebrocardiovascular events. Hepatitis C virus (HCV) infection is a common cause of chronic liver disease worldwide and is associated with greater mortality compared with that in the general population or even mortality associated with HIV infection. Although liver disease and liver cirrhosis account for the bulk of HCV-related disease burden and deaths, it is becoming increas

The Week in Review: July 21 – July 28, 2017

Friday, July 28, 2017 News Recap WHD 2017 Victoria, BC in Pictures The weather was perfect; the organization and volunteers did great!!!!  The speakers were fabulous!! I only wish more people had shown up!!!  Big thanks to VPWAS and AVI for helping to make this important event a reality! Click on photos to see larger image in a new window! Should we be worried about hepatitis E? Hepatitis E virus infection (HEV) is the most common cause of a...

Liver transplant news to know: Complication prediction and more

Liver transplant indications vary depending on disease — from hepatitis C, to alcoholic liver disease, to cholestatic diseases such as primary biliary cholangitis and primary sclerosing cholangitis. Healio.com/Hepatology presents the top liver transplant studies for July 2017, which include an online app designed to predict cardiovascular complication posttransplant, higher rates of donation among patients with risk exceptions in Eurotransplant countries,

Cardiovascular disease risk is higher for people with hepatitis C

People with hepatitis C are at higher risk of dying from cardiovascular disease suffering a stroke or developing cardiovascular problems than people with similar risk factors for heart disease who do not have hepatitis C, a meta-analysis of published studies has shown.The findings, published in the January 2016 edition of Gastroenterology, come from a meta-analysis of 22 epidemiological studies conducted by Salvatore Petta and colleagues at the University